CymaBay Therapeutics Q4 EPS $(0.35) Misses $(0.31) Estimate
Portfolio Pulse from Happy Mohamed
CymaBay Therapeutics reported Q4 EPS of $(0.35), missing the consensus estimate of $(0.31) by 12.9%. This represents a 16.67% increase in losses compared to the same period last year.
February 28, 2024 | 10:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
CymaBay Therapeutics reported a larger than expected quarterly loss, missing analyst estimates and showing an increase in losses from the previous year.
Missing earnings estimates, especially with an increase in losses year-over-year, is generally viewed negatively by the market. This could lead to a decrease in investor confidence and a potential short-term decline in CBAY's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100